Compound ID | 1784
RESP-X
Synonym(s): COT-143 | INFEX702
Class: null
| Agent Type: | Direct acting; Antibody; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Targets the PcrV protein |
| Target Pathogen: | Active against Pseudomonas aeruginosa |
| Description: | Humanised monoclonal antibody; developed for non-cystic fibrosis bronchiectasis |
| Institute where first reported: | Infex Therapeutics (formerly AMR Center), Shionogi, Colibri Scientific |
| Year first mentioned: | 2019 |
| Highest development stage: | Phase 2a |
| Development status: | Active |
| External links: | |
| Guide to Pharmacology: | RESP-X |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.